Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Celgene
Biotech
BMS calls time on Zymeworks collab, ending work on bispecific
The decision was made "as part of our ongoing prioritization efforts," a BMS spokesperson told Fierce.
James Waldron
Apr 30, 2026 10:22am
Ex-Celgene CEO takes the top job at TORL—Chutes & Ladders
Jan 12, 2024 9:30am
Flagship snags former BMS R&D chief Vessey as chief scientist
Jul 13, 2023 8:00am
Billy Dunn departs FDA—Chutes & Ladders
Mar 3, 2023 9:30am
Embattled Sorrento files for bankruptcy amid ongoing legal fight
Feb 13, 2023 11:20am
SPAC to it: Alzheimer's-focused Aprinoia set to go public
Jan 18, 2023 12:44pm
